金花股份,600080,收入构成,报告日期,2020-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),24,9,15,63.37%,0.03% 普药类,4312,3127,1185,27.48%,2.54% 免疫类,5645,2574,3071,54.4%,6.58% 骨科类,47548,5910,41638,87.57%,89.2% 儿童类,1279,507,772,60.34%,1.65% 金花股份,600080,收入构成,报告日期,2020-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 医药商业,2864,2771,93,3.24%,0.52% 医药工业,22539,4695,17844,79.17%,99.56% 酒店业,672,687,-15,-2.18%,-0.08% 分部间抵销,-62,-- ,-- ,--,0% 金花股份,600080,收入构成,报告日期,2019-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 儿童类,1699,650,1049,61.73%,2.02% 普药类,4510,3093,1417,31.42%,2.72% 骨科类,52137,5713,46425,89.04%,89.17% 其他(补充),115,16,99,85.92%,0.19% 免疫类,5124,2050,3074,59.99%,5.9% 金花股份,600080,收入构成,报告日期,2019-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 分部间抵销,-203,-- ,-- ,--,0% 医药工业,28945,5334,23611,81.57%,95.77% 医药商业,4075,3673,401,9.85%,1.63% 酒店业,1796,1155,642,35.72%,2.6% 金花股份,600080,收入构成,报告日期,2018-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),115,17,98,85.6%,0.2% 免疫类,4535,1748,2787,61.45%,5.72% 骨科类,48113,4817,43296,89.99%,88.92% 儿童类,1580,565,1015,64.25%,2.08% 普药类,4302,2805,1497,34.8%,3.07% 金花股份,600080,收入构成,报告日期,2018-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 医药商业,6343,5843,500,7.88%,2.14% 医药工业,26799,4905,21894,81.7%,93.73% 酒店业,2216,1251,965,43.55%,4.13% 金花股份,600080,收入构成,报告日期,2017-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 骨科类,46244,4512,41732,90.24%,89.97% 免疫类,3797,1450,2348,61.82%,5.06% 儿童类,1372,510,862,62.82%,1.86% 普药类,4483,3149,1334,29.76%,2.88% 其他(补充),126,18,108,85.42%,0.23% 金花股份,600080,收入构成,报告日期,2017-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 医药商业,7862,7486,376,4.78%,1.65% 酒店业,1820,1159,661,36.34%,2.9% 医药工业,26401,4596,21804,82.59%,95.46% 金花股份,600080,收入构成,报告日期,2016-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),131,16,114,87.57%,0.28% 普药类,3934,2738,1196,30.4%,2.96% 儿童类,1057,403,654,61.89%,1.62% 免疫类,3215,1253,1962,61.03%,4.85% 骨科类,40414,3915,36499,90.31%,90.29% 金花股份,600080,收入构成,报告日期,2016-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 酒店行业,2886,1847,1039,36.01%,1.76% 医药商业,9774,9354,421,4.3%,0.71% 其中:普药类,2683,1915,768,28.63%,1.3% 其中:小儿类,750,285,465,62.05%,0.79% 其中:免疫类,2297,914,1382,60.19%,2.35% 其中:骨科类,29193,3070,26123,89.48%,44.32% 医药工业,34923,6184,28739,82.29%,48.76% 金花股份,600080,收入构成,报告日期,2016-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 酒店行业,1692,1211,481,28.41%,1.29% 医药商业,6448,6177,270,4.2%,0.72% 其中:普药类,1717,1261,456,26.55%,1.22% 其中:小儿类,482,185,297,61.7%,0.8% 其中:免疫类,1365,563,801,58.72%,2.14% 其中:骨科类,18778,2025,16753,89.22%,44.83% 医药工业,22341,4034,18307,81.94%,48.99% 金花股份,600080,收入构成,报告日期,2015-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),122,22,99,81.63%,0.32% 普药类,3296,2261,1034,31.38%,3.28% 儿童类,1106,363,743,67.17%,2.36% 免疫类,2485,889,1596,64.23%,5.07% 骨科类,31213,3182,28030,89.8%,88.98% 金花股份,600080,收入构成,报告日期,2003-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 转移因子,6458,1093,5365,83.08%,100% 金花股份,600080,收入构成,报告日期,2003-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 租赁收入,1050,595,455,43.37%,8.26% 保健品,335,204,131,39.14%,2.38% 药品,13258,8333,4925,37.15%,89.36% 金花股份,600080,收入构成,报告日期,2003-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钟鼓楼广场项目,525,297,228,43.37%,13.25% 转移因子口服液,1790,299,1491,83.32%,86.75% 金花股份,600080,收入构成,报告日期,2002-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钟鼓楼广场项目,2100,1186,914,43.54%,8.39% 保健品,306,146,160,52.38%,1.47% 药品,15797,5980,9816,62.14%,90.13% 金花股份,600080,收入构成,报告日期,2001-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 钟鼓楼广场项目,2100,864,1236,58.84%,13.35% 转移因子口服液,9154,1134,8020,87.61%,86.65%